Filtered By:
Drug: Beta-Blockers
Education: Study
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 332 results found since Jan 2013.
Association of beta-blocker therapy at discharge with clinical outcomes in patients without heart failure or left ventricular systolic dysfunction after acute coronary syndrome: An updated systematic review and meta-analysis
CONCLUSIONS: In patients without heart failure or left ventricular systolic dysfunction after ACS in the contemporary PCI era, beta-blocker therapy may still be beneficial due to a potential reduced risk of all-cause death.PMID:36376209 | DOI:10.1016/j.acvd.2022.09.004
Source: Archives of Cardiovascular Diseases - November 14, 2022 Category: Cardiology Authors: Meng-Jin Hu Xiao-Ning Wang Jiang-Shan Tan Yue-Jin Yang Source Type: research
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis
ConclusionCurrent clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.
Source: European Journal of Clinical Pharmacology - October 12, 2022 Category: Drugs & Pharmacology Source Type: research
Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: Results from a global meta-analysis of 1,285,722 patients
CONCLUSION: In this study level meta-analysis, SMuRF-less ACS patients demonstrate higher mortality compared with patients with at least one traditional atherosclerotic risk factor. Underuse of guideline-directed medical therapy amongst SMuRF-less patients is concerning. Unraveling novel risk factors amongst SMuRF-less individuals is the next important step.SUMMARY: Standard modifiable cardiovascular risk factors (SMuRF), comprising diabetes mellitus, hyperlipidemia, hypertension, and smoking, are often used for risk stratification in acute coronary syndrome (ACS). Recent studies showed an increasing proportion of SMuRF-le...
Source: Atherosclerosis - September 30, 2022 Category: Cardiology Authors: Gwyneth Kong Yip Han Chin Bryan Chong Rachel Sze Jen Goh Oliver Zi Hern Lim Cheng Han Ng Mark Muthiah Roger Foo Stephen T Vernon Poay Huan Loh Mark Y Chan Nicholas W S Chew Gemma A Figtree Source Type: research
Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis
CONCLUSION: Current clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.PMID:36136141 | DOI:10.1007/s00228-022-03383-2
Source: Clinical Lung Cancer - September 22, 2022 Category: Cancer & Oncology Authors: Xiaomei Wang Demei Zhang Yanxia Ren Jingjing Han Guangling Li Xueya Guo Source Type: research
Clinical impact of beta-blockers at discharge on long-term clinical outcomes in patients with non-reduced ejection fraction after acute myocardial infarction
CONCLUSIONS: The J-MINUET study revealed the clinical benefit of beta-blockers in AMI patients with non-REF after primary PCI.PMID:35995686 | DOI:10.1016/j.jjcc.2022.08.002
Source: Journal of Cardiology - August 22, 2022 Category: Cardiology Authors: Azusa Sakagami Tsunenari Soeda Yoshihiko Saito Koichi Nakao Yukio Ozaki Kazuo Kimura Junya Ako Teruo Noguchi Satoru Suwa Kazuteru Fujimoto Kazuoki Dai Takashi Morita Wataru Shimizu Atsushi Hirohata Yasuhiro Morita Teruo Inoue Atsunori Okamura Toshiaki Man Source Type: research
